Skip to main content
SpringerLink
Log in

BRAF Mutations in CNS Tumors—Prognostic Markers and Therapeutic Targets

  • Review Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Gliomas are a heterogeneous group of brain tumors with limited therapeutic options. However, identification of BRAF V600E mutations in a subset of gliomas has provided a genomic-targeted approach for management of these diseases. In this review, we aimed to review the role of BRAF V600E in gliomagenesis, to characterize concurrent genomic alterations and their potential prognostic implications, and to review comprehensively the efficacy data of BRAF inhibitors (combined or not with MEK inhibitors) for the treatment of low- and high-grade gliomas. We also provide a summary of the toxicity of these agents and describe resistance mechanisms that may be circumvented by alternative genomic approaches. Although the efficacy of targeted therapy for management of BRAF V600E-mutant gliomas has mostly been assessed in small retrospective and phase 2 studies with heterogeneous populations, the data generated so far are a proof of concept that genomic-directed therapies improve outcomes of patients with refractory/relapsed glioma and underpin the need of comprehensive genomic assessments for these difficult-to-treat diseases. In the future, the role of targeted therapy in the first-line setting and of genomic-directed therapies to overcome resistance mechanisms should be assessed in well-designed clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data availability

Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

References

  1. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO Classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231–51.

    CAS  PubMed  PubMed Central  Google Scholar 

  2. van der Meulen M, Ramos RC, Mason WP, Von Deimling A, Maas SLN. Opinion & Special Article: Glioma classification: how to interpret molecular markers in a diffuse glioma pathology report. Neurology. 2022 Sep 2.

  3. Mohile NA, Messersmith H, Gatson NTN, Hottinger AF, Lassman AB, Morton J, et al. Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO Guideline. J Clin Oncol. 2022;24(3):358–83.

    Google Scholar 

  4. de Blank P, Bandopadhayay P, Haas-Kogan D, Fouladi M, Fangusaro J. Management of pediatric low-grade glioma. Curr Opin Pediatr. 2019;31(1):21–7.

    PubMed  PubMed Central  Google Scholar 

  5. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.

    CAS  PubMed  Google Scholar 

  6. Minniti G, De Sanctis V, Muni R, Filippone F, Bozzao A, Valeriani M, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. J Neurooncol. 2008;88(1):97–103.

    CAS  PubMed  Google Scholar 

  7. Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318(23):2306–16.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, et al. Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med. 2017;377(20):1954–63.

    CAS  PubMed  Google Scholar 

  9. Dummer R, Hauschild A, Santinami M, Atkinson V, Mandalà M, Kirkwood JM, et al. Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma. N Engl J Med. 2020;383(12):1139–48.

    CAS  PubMed  Google Scholar 

  10. Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol. 2019;30(11):1848.

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Dummer R, Flaherty KT, Robert C, Arance A, de Groot JWB, Garbe C, et al. COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. J Clin Oncol. 2022;40(36):4178–88.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Tabernero J, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, et al. Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study. J Clin Oncol. 2021;39(4):273–84.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Ascierto PA, McArthur GA, Dreno B, Atkinson V, Liszkay G, Di Giacomo AM, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17(9):1248–60.

    CAS  PubMed  Google Scholar 

  14. Ye Q, Srivastava P, Al-Kuwari N, Chen X. Oncogenic BRAF(V600E) induces microglial proliferation through extracellular signal-regulated kinase and neuronal death through c-Jun N-terminal kinase. Neural Regen Res. 2023;18(7):1613–22.

    PubMed  Google Scholar 

  15. Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, et al. OncoKB: a precision oncology knowledge base. JCO Precis Oncol. 2017;2017.

  16. Saginala K, Barsouk A, Aluru JS, Rawla P, Barsouk A. Epidemiology of melanoma. Med Sci. 2021;9(4).

  17. Grothey A, Fakih M, Tabernero J. Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines. Ann Oncol. 2021;32(8):959–67.

    CAS  PubMed  Google Scholar 

  18. Leonetti A, Facchinetti F, Rossi G, Minari R, Conti A, Friboulet L, et al. BRAF in non-small cell lung cancer (NSCLC): pickaxing another brick in the wall. Cancer Treat Rev. 2018;66:82–94.

    CAS  PubMed  Google Scholar 

  19. Scheffel RS, Dora JM, Maia AL. BRAF mutations in thyroid cancer. Curr Opin Oncol. 2022;34(1):9–18.

    CAS  PubMed  Google Scholar 

  20. Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 2011;121(3):397–405.

    CAS  PubMed  Google Scholar 

  21. Vuong HG, Altibi AMA, Duong UNP, Ngo HTT, Pham TQ, Fung KM, et al. BRAF mutation is associated with an improved survival in glioma-a systematic review and meta-analysis. Mol Neurobiol. 2018;55(5):3718–24.

    CAS  PubMed  Google Scholar 

  22. Wang W, Wang M, Jiang H, Wang T, Da R. BRAF(non-V600E) more frequently co-occurs with IDH1/2 mutations in adult patients with gliomas than in patients harboring BRAF(V600E) but without a survival advantage. BMC Neurol. 2021;21(1):195.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Dahiya S, Haydon DH, Alvarado D, Gurnett CA, Gutmann DH, Leonard JR. BRAF(V600E) mutation is a negative prognosticator in pediatric ganglioglioma. Acta Neuropathol. 2013;125(6):901–10.

    CAS  PubMed  Google Scholar 

  24. Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland A, et al. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017;18(10):1307–16.

    CAS  PubMed  Google Scholar 

  25. Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol. 2018;36(1):7–13.

    CAS  PubMed  Google Scholar 

  26. Kaley T, Touat M, Subbiah V, Hollebecque A, Rodon J, Lockhart AC, et al. BRAF inhibition in BRAF(V600)-mutant gliomas: results from the VE-BASKET study. J Clin Oncol. 2018;36(35):3477–84.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Wen PY, Stein A, van den Bent M, De Greve J, Wick A, de Vos F, et al. Dabrafenib plus trametinib in patients with BRAF(V600E)-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. Lancet Oncol. 2022;23(1):53–64.

    CAS  PubMed  Google Scholar 

  28. Subbiah V, Kreitman RJ, Wainberg ZA, Gazzah A, Lassen U, Stein A, et al. Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. Nat Med. 2023 Apr 14.

  29. Salama AKS, Li S, Macrae ER, Park JI, Mitchell EP, Zwiebel JA, et al. Dabrafenib and trametinib in patients with tumors with BRAF(V600E) mutations: results of the NCI-MATCH trial subprotocol H. J Clin Oncol. 2020;38(33):3895–904.

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Nobre L, Zapotocky M, Ramaswamy V, Ryall S, Bennett J, Alderete D, et al. Outcomes of BRAF V600E pediatric gliomas treated with targeted BRAF inhibition. JCO Precis Oncol. 2020;4.

  31. Berzero G, Bellu L, Baldini C, Ducray F, Guyon D, Eoli M, et al. Sustained tumor control with MAPK inhibition in BRAF V600-mutant adult glial and glioneuronal tumors. Neurology. 2021;97(7):e673–83.

    CAS  PubMed  Google Scholar 

  32. Perez JPM, Muchart J, Lopez VS, Capella MS, Salvador N, Jaume SP, et al. Targeted therapy for pediatric low-grade glioma. Childs Nerv Syst. 2021;37(8):2511–20.

    PubMed  Google Scholar 

  33. Di Nunno V, Gatto L, Tosoni A, Bartolini S, Franceschi E. Implications of BRAF V600E mutation in gliomas: Molecular considerations, prognostic value and treatment evolution. Front Oncol. 2022;12:1067252.

    CAS  PubMed  Google Scholar 

  34. Dankner M, Rose AAN, Rajkumar S, Siegel PM, Watson IR. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. Oncogene. 2018;37(24):3183–99.

    CAS  PubMed  Google Scholar 

  35. Schreck KC, Grossman SA, Pratilas CA. BRAF mutations and the utility of RAF and MEK inhibitors in primary brain tumors. Cancers. 2019;11(9).

  36. Jones DT, Kocialkowski S, Liu L, Pearson DM, Backlund LM, Ichimura K, et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 2008;68(21):8673–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Andrews LJ, Thornton ZA, Saincher SS, Yao IY, Dawson S, McGuinness LA, et al. Prevalence of BRAFV600 in glioma and use of BRAF inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review. Neuro Oncol. 2022;24(4):528–40.

    CAS  PubMed  Google Scholar 

  38. Ryall S, Zapotocky M, Fukuoka K, Nobre L, Guerreiro Stucklin A, Bennett J, et al. Integrated molecular and clinical analysis of 1,000 pediatric low-grade gliomas. Cancer Cell. 2020;37(4):569-83 e5.

  39. Dono A, Vu J, Anapolsky M, Hines G, Takayasu T, Yan Y, et al. Additional genetic alterations in BRAF-mutant gliomas correlate with histologic diagnoses. J Neurooncol. 2020;149(3):463–72.

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Omura T, Takahashi M, Ohno M, Miyakita Y, Yanagisawa S, Tamura Y, et al. Clinical application of comprehensive genomic profiling tests for diffuse gliomas. Cancers. 2022;14(10).

  41. Lazow MA, Hoffman L, Schafer A, Osorio DS, Boue DR, Rush S, et al. Characterizing temporal genomic heterogeneity in pediatric low-grade gliomas. Acta Neuropathol Commun. 2020;8(1):182.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. 2014;343(6167):189–93.

    CAS  PubMed  Google Scholar 

  43. Ellison DW, Hawkins C, Jones DTW, Onar-Thomas A, Pfister SM, Reifenberger G, et al. cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAF(V600E) mutation. Acta Neuropathol. 2019;137(4):683–7.

    CAS  PubMed  Google Scholar 

  44. Raabe EH, Lim KS, Kim JM, Meeker A, Mao XG, Nikkhah G, et al. BRAF activation induces transformation and then senescence in human neural stem cells: a pilocytic astrocytoma model. Clin Cancer Res. 2011;17(11):3590–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  45. Huillard E, Hashizume R, Phillips JJ, Griveau A, Ihrie RA, Aoki Y, et al. Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy. Proc Natl Acad Sci USA. 2012;109(22):8710–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  46. Prabowo AS, Iyer AM, Veersema TJ, Anink JJ, Schouten-van Meeteren AY, Spliet WG, et al. BRAF V600E mutation is associated with mTOR signaling activation in glioneuronal tumors. Brain Pathol. 2014;24(1):52–66.

    CAS  PubMed  Google Scholar 

  47. Wang J, Liu Z, Cui Y, Liu Y, Fang J, Xu L, et al. Evaluation of EZH2 expression, BRAF V600E mutation, and CDKN2A/B deletions in epithelioid glioblastoma and anaplastic pleomorphic xanthoastrocytoma. J Neurooncol. 2019;144(1):137–46.

    CAS  PubMed  Google Scholar 

  48. Frazão L, do Carmo Martins M, Nunes VM, Pimentel J, Faria C, Miguéns J, et al. BRAF V600E mutation and 9p21: CDKN2A/B and MTAP co-deletions–markers in the clinical stratification of pediatric gliomas. BMC Cancer. 2018;18(1).

  49. Gabler L, Lotsch D, Kirchhofer D, van Schoonhoven S, Schmidt HM, Mayr L, et al. TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF(V600E)/TERT promoter double-mutated glioma. Acta Neuropathol Commun. 2019;7(1):128.

    PubMed  PubMed Central  Google Scholar 

  50. Fukuoka K, Mamatjan Y, Ryall S, Komosa M, Bennett J, Zapotocky M, et al. BRAF V600E mutant oligodendroglioma-like tumors with chromosomal instability in adolescents and young adults. Brain Pathol. 2020;30(3):515–23.

    CAS  PubMed  Google Scholar 

  51. Pages M, Beccaria K, Boddaert N, Saffroy R, Besnard A, Castel D, et al. Co-occurrence of histone H3 K27M and BRAF V600E mutations in paediatric midline grade I ganglioglioma. Brain Pathol. 2018;28(1):103–11.

    CAS  PubMed  Google Scholar 

  52. Schiffman JD, Hodgson JG, VandenBerg SR, Flaherty P, Polley MY, Yu M, et al. Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res. 2010;70(2):512–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  53. Lassaletta A, Zapotocky M, Mistry M, Ramaswamy V, Honnorat M, Krishnatry R, et al. Therapeutic and prognostic implications of BRAF V600E in pediatric low-grade gliomas. J Clin Oncol. 2017;35(25):2934–41.

    CAS  PubMed  PubMed Central  Google Scholar 

  54. Tan JY, Wijesinghe IVS, Alfarizal Kamarudin MN, Parhar I. Paediatric gliomas: BRAF and Histone H3 as biomarkers, therapy and perspective of liquid biopsies. Cancers. 2021;13(4).

  55. Davies MA, Saiag P, Robert C, Grob J-J, Flaherty KT, Arance A, et al. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 2017;18(7):863–73.

    CAS  PubMed  PubMed Central  Google Scholar 

  56. Usta D, Sigaud R, Buhl JL, Selt F, Marquardt V, Pauck D, et al. A cell-based MAPK reporter assay reveals synergistic MAPK pathway activity suppression by MAPK inhibitor combination in BRAF-driven pediatric low-grade glioma cells. Mol Cancer Ther. 2020;19(8):1736–50.

    CAS  PubMed  Google Scholar 

  57. Zhang J, Yao TW, Hashizume R, Hariono S, Barkovich KJ, Fan QW, et al. Combined BRAF(V600E) and MEK blockade for BRAF(V600E)-mutant gliomas. J Neurooncol. 2017;131(3):495–505.

    CAS  PubMed  Google Scholar 

  58. Grossauer S, Koeck K, Murphy NE, Meyers ID, Daynac M, Truffaux N, et al. Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model. Oncotarget. 2016;7(46):75839–53.

    PubMed  PubMed Central  Google Scholar 

  59. Johanns TM, Ferguson CJ, Grierson PM, Dahiya S, Ansstas G. Rapid clinical and radiographic response with combined dabrafenib and trametinib in adults with BRAF-mutated high-grade glioma. J Natl Compr Canc Netw. 2018;16(1):4–10.

    PubMed  Google Scholar 

  60. Costa IN, Reis J, Pinheiro J, Silva R, Fernandes C. Dabrafenib plus trametinib: an impressive response in an adult patient with BRAF V600E-mutated and isocitrate dehydrogenase (IDH) wild-type glioma. Cureus. 2022;14(8): e28156.

    PubMed  PubMed Central  Google Scholar 

  61. Fusco MJ, Pina Y, Macaulay RJ, Sahebjam S, Forsyth PA, Peguero E, et al. Durable progression-free survival with the use of BRAF and MEK inhibitors in four cases with BRAF V600E-mutated gliomas. Cancer Control. 2021;28:10732748211040012.

    PubMed  PubMed Central  Google Scholar 

  62. Toll SA, Tran HN, Cotter J, Judkins AR, Tamrazi B, Biegel JA, et al. Sustained response of three pediatric BRAF(V600E) mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy. Oncotarget. 2019;10(4):551–7.

    PubMed  PubMed Central  Google Scholar 

  63. Schreck KC, Guajardo A, Lin DDM, Eberhart CG, Grossman SA. Concurrent BRAF/MEK inhibitors in BRAF V600-mutant high-grade primary brain tumors. J Natl Compr Canc Netw. 2018;16(4):343–7.

    PubMed  Google Scholar 

  64. Smith-Cohn M, Davidson C, Colman H, Cohen AL. Challenges of targeting BRAF V600E mutations in adult primary brain tumor patients: a report of two cases. CNS Oncol. 2019;8(4):CNS48.

  65. Del Bufalo F, Ceglie G, Cacchione A, Alessi I, Colafati GS, Carai A, et al. BRAF V600E inhibitor (vemurafenib) for BRAF V600E mutated low grade gliomas. Front Oncol. 2018;8:526.

    PubMed  PubMed Central  Google Scholar 

  66. Hargrave DR, Bouffet E, Tabori U, Broniscer A, Cohen KJ, Hansford JR, et al. Efficacy and safety of dabrafenib in pediatric patients with BRAF V600 mutation-positive relapsed or refractory low-grade glioma: results from a phase I/IIa study. Clin Cancer Res. 2019;25(24):7303–11.

    CAS  PubMed  Google Scholar 

  67. Nicolaides T, Nazemi KJ, Crawford J, Kilburn L, Minturn J, Gajjar A, et al. Phase I study of vemurafenib in children with recurrent or progressive BRAF(V600E) mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002). Oncotarget. 2020;11(21):1942–52.

    PubMed  PubMed Central  Google Scholar 

  68. Bouffet E, Geoerger B, Moertel C, Whitlock JA, Aerts I, Hargrave D, et al. Efficacy and safety of trametinib monotherapy or in combination with dabrafenib in pediatric BRAF V600-mutant low-grade glioma. J Clin Oncol. 2023;41(3):664–74.

    CAS  PubMed  Google Scholar 

  69. Eric Bouffet JH, Maria Luisa Garré, Junichi Hara, Ashley Plant-Fox, Isabelle Aerts, Franco Locatelli, Jasper Van der Lugt, Ludmila Papusha, Felix Sahm, Uri Tabori, Kenneth J. Cohen, Roger J. Packer, Olaf Witt, Lali Sandalic, Ana Bento Pereira da Silva, Mark W. Russo, and Darren R. Hargrave. Primary analysis of a phase II trial of dabrafenib plus trametinib (dab + tram) in BRAF V600-mutant pediatric low-grade glioma (pLGG). J Clin Oncol. 2022 40:17_suppl, LBA2002-LBA2002.

  70. Leclair NK, Lambert W, Roche K, Gillan E, Gell JJ, Lau CC, et al. Early experience with targeted therapy as a first-line adjuvant treatment for pediatric low-grade glioma. Neurosurg Focus. 2022;53(6):E15.

    PubMed  Google Scholar 

  71. Rosenberg T, Yeo KK, Mauguen A, Alexandrescu S, Prabhu SP, Tsai JW, et al. Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma. Neuro Oncol. 2022;24(11):1964–75.

    CAS  PubMed  PubMed Central  Google Scholar 

  72. Darren R. Hargrave KT, Junichi Hara, Uwe R. Kordes, Santhosh A. Upadhyaya, Felix Sahm, Eric Bouffet, Roger J. Packer, Olaf Witt, Lali Sandalic, Agnieszka Kieloch, Mark W. Russo, and Kenneth J. Cohen. Dabrafenib + trametinib (dab + tram) in relapsed:refractory (r:r) BRAF V600–mutant pediatric high-grade glioma (pHGG)- Primary analysis of a phase II trial. 2022;DOI: https://doi.org/10.1200/JCO.2022.40.16_suppl.2009 J Clin Oncol. 40, no. 16_suppl (June 01, 2022) 2009-2009.

  73. Karisa Schreck RS, L Burt Nabors, Ben Ellingson, Joy Fisher, Serena Desideri, Neeraja Danda, Michelle Rudek, Stuart Grossman, Xiaobu Ye. CTNI-60. Preliminary results of binimetinib and encorafenib in adults with recurrent BRAF V600E-mutated high-grade glioma. Neurooncology. 2022;24,7:vii86, https://doi.org/10.1093/neuonc/noac209325

  74. Ascierto PA, Dummer R, Gogas HJ, Flaherty KT, Arance A, Mandala M, et al. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. Eur J Cancer. 2020;126:33–44.

    CAS  PubMed  Google Scholar 

  75. Larkin J, Ascierto PA, Dreno B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867–76.

    PubMed  Google Scholar 

  76. Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):603–15.

    CAS  PubMed  Google Scholar 

  77. Mincu RI, Mahabadi AA, Michel L, Mrotzek SM, Schadendorf D, Rassaf T, et al. Cardiovascular adverse events associated with BRAF and MEK inhibitors: a systematic review and meta-analysis. JAMA Netw Open. 2019;2(8): e198890.

    PubMed  PubMed Central  Google Scholar 

  78. Glen C, Tan YY, Waterston A, Evans TRJ, Jones RJ, Petrie MC, et al. Mechanistic and clinical overview cardiovascular toxicity of BRAF and MEK inhibitors: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2022;4(1):1–18.

    PubMed  PubMed Central  Google Scholar 

  79. Atkinson V, Robert C, Grob JJ, Gogas H, Dutriaux C, Demidov L, et al. Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: primary results of COMBI-APlus. Eur J Cancer. 2022;163:79–87.

    CAS  PubMed  Google Scholar 

  80. Li L, Fang S, Li G, Zhang K, Huang R, Wang Y, et al. Glioma-related epilepsy in patients with diffuse high-grade glioma after the 2016 WHO update: seizure characteristics, risk factors, and clinical outcomes. J Neurosurg. 2022;136(1):67–75.

    CAS  PubMed  Google Scholar 

  81. Dreno B, Ribas A, Larkin J, Ascierto PA, Hauschild A, Thomas L, et al. Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study. Ann Oncol. 2017;28(5):1137–44.

    CAS  PubMed  Google Scholar 

  82. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694–703.

    CAS  PubMed  PubMed Central  Google Scholar 

  83. Touat M, Gratieux J, Condette Auliac S, Sejean K, Aldea S, Savatovsky J, et al. Vemurafenib and cobimetinib overcome resistance to vemurafenib in BRAF-mutant ganglioglioma. Neurology. 2018;91(11):523–5.

    PubMed  PubMed Central  Google Scholar 

  84. Schreck KC, Morin A, Zhao G, Allen AN, Flannery P, Glantz M, et al. Deconvoluting mechanisms of acquired resistance to RAF inhibitors in BRAF(V600E)-mutant human glioma. Clin Cancer Res. 2021;27(22):6197–208.

    CAS  PubMed  PubMed Central  Google Scholar 

  85. Yao TW, Zhang J, Prados M, Weiss WA, James CD, Nicolaides T. Acquired resistance to BRAF inhibition in BRAFV600E mutant gliomas. Oncotarget. 2017;8(1):583–95.

    PubMed  Google Scholar 

  86. Wang J, Yao Z, Jonsson P, Allen AN, Qin ACR, Uddin S, et al. A secondary mutation in BRAF confers resistance to RAF inhibition in a BRAF(V600E)-mutant brain tumor. Cancer Discov. 2018;8(9):1130–41.

    CAS  PubMed  PubMed Central  Google Scholar 

  87. Jain P, Fierst TM, Han HJ, Smith TE, Vakil A, Storm PB, et al. CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles. Oncogene. 2017;36(45):6348–58.

    CAS  PubMed  PubMed Central  Google Scholar 

  88. Yao TW, Zhang J, Prados M, Weiss WA, James CD, Nicolaides T. EGFR blockade prevents glioma escape from BRAFV600E targeted therapy. Oncotarget. 2015;6(26):21993–2005.

    PubMed  PubMed Central  Google Scholar 

  89. Mulcahy Levy JM, Zahedi S, Griesinger AM, Morin A, Davies KD, Aisner DL, et al. Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors. Elife. 2017;6.

  90. Levy JM, Thompson JC, Griesinger AM, Amani V, Donson AM, Birks DK, et al. Autophagy inhibition improves chemosensitivity in BRAF(V600E) brain tumors. Cancer Discov. 2014;4(7):773–80.

    CAS  PubMed  PubMed Central  Google Scholar 

  91. Pina Y, Fusco MJ, Macaulay RJ, Walko CM, Peguero E, Evernden BR, et al. Using personalized medicine in gliomas: a genomic approach to diagnosis and overcoming treatment resistance in a case with pleomorphic xanthoastrocytoma. J Neurol. 2020;267(3):783–90.

    CAS  PubMed  Google Scholar 

  92. Maxwell MJ, Arnold A, Sweeney H, Chen L, Lih TM, Schnaubelt M, et al. Unbiased proteomic and phosphoproteomic analysis identifies response signatures and novel susceptibilities after combined MEK and mTOR inhibition in BRAF(V600E) mutant glioma. Mol Cell Proteomics. 2021;20: 100123.

    CAS  PubMed  PubMed Central  Google Scholar 

  93. Sasame J, Ikegaya N, Kawazu M, Natsumeda M, Hayashi T, Isoda M, et al. HSP90 inhibition overcomes resistance to molecular targeted therapy in BRAFV600E-mutant high-grade glioma. Clin Cancer Res. 2022;28(11):2425–39.

    CAS  PubMed  Google Scholar 

  94. Bid HK, Kibler A, Phelps DA, Manap S, Xiao L, Lin J, et al. Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma. Clin Cancer Res. 2013;19(24):6716–29.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada

    Thiago P. Muniz & Warren P. Mason

Authors
  1. Thiago P. Muniz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Warren P. Mason
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thiago P. Muniz.

Ethics declarations

Funding

No external funding was used in the preparation of this manuscript.

Conflict of Interest

Thiago P. Muniz is a prior recipient of the Novartis Oncology Young Canadian Investigator Award. Warren P. Mason has received honoraria from Bayer, Viatris, Inc., and GlaxoSmithKline, and is part of the advisory board for Novocure.

Ethics Approval

Not applicable.

Consent to Participate

Not applicable.

Consent for Publication

Not applicable.

Code Availability

Not applicable.

Author Contributions

Thiago P. Muniz: conceptualization, methodology, data curation, writing—original draft, writing—review and editing. Warren P. Mason: conceptualization, writing—review and editing, supervision.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Muniz, T.P., Mason, W.P. BRAF Mutations in CNS Tumors—Prognostic Markers and Therapeutic Targets. CNS Drugs 37, 587–598 (2023). https://doi.org/10.1007/s40263-023-01016-5

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40263-023-01016-5

Search

Navigation